Thanks to new funding from the National Institutes of Health and private donors, we now offer three ways that WRAP participants can engage in biomarker research: lumbar puncture (LP), MRI scanning, and PET scanning. The data is most valuable when combined and compared to the cognitive testing.
The Wisconsin Registry for Alzheimer’s Prevention has set a goal of gathering biomarker data from all of our eligible participants. This data is the future of Alzheimer’s disease research at UW and around the world.
Biomarkers are measures, gained through laboratory and imaging tests, which provide information about the stage and severity of specific diseases. The WRAP study is investigating biomarkers of Alzheimer’s disease (AD), and related disorders including vascular disease. Biomarker information gathered over time, through all three methods listed below, and in conjunction with cognitive testing, provides a detailed picture of normal and abnormal brain changes, risk and resiliency characteristics, and the disease course. Through biomarkers, it is possible to see changes in people’s brains many years before other symptoms appear.